Max Flogegård

1.1k total citations
9 papers, 112 citations indexed

About

Max Flogegård is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Hematology. According to data from OpenAlex, Max Flogegård has authored 9 papers receiving a total of 112 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 4 papers in Molecular Biology and 4 papers in Hematology. Recurrent topics in Max Flogegård's work include Lymphoma Diagnosis and Treatment (5 papers), Multiple Myeloma Research and Treatments (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Max Flogegård is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Multiple Myeloma Research and Treatments (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Max Flogegård collaborates with scholars based in Sweden, Norway and Denmark. Max Flogegård's co-authors include Gunilla Enblad, Hareth Nahi, Antonios Valachis, Björn Andréasson, Per‐Ola Andersson, Niels Frost Andersen, Lene Meldgaard Knudsen, Rolf Billström, Agneta Swedin and Nina Gulbrandsen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Max Flogegård

8 papers receiving 110 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Flogegård Sweden 6 68 51 45 29 14 9 112
Camila Peña Chile 6 36 0.5× 54 1.1× 43 1.0× 28 1.0× 4 0.3× 43 111
Weerasak Nawarawong Thailand 8 55 0.8× 119 2.3× 36 0.8× 25 0.9× 7 0.5× 25 167
Donata Sartori Italy 6 72 1.1× 17 0.3× 22 0.5× 22 0.8× 13 0.9× 18 126
Kayleen Bailey United States 5 29 0.4× 27 0.5× 79 1.8× 8 0.3× 6 0.4× 10 136
Gian Matteo Pica France 7 40 0.6× 49 1.0× 25 0.6× 31 1.1× 10 0.7× 16 89
Hong L. Tiv United States 5 40 0.6× 50 1.0× 68 1.5× 13 0.4× 3 0.2× 7 130
Holly Lee Canada 9 94 1.4× 100 2.0× 99 2.2× 10 0.3× 35 2.5× 37 187
Jorge Monge United States 7 46 0.7× 72 1.4× 68 1.5× 21 0.7× 7 0.5× 15 119
Chiara Pavoni Italy 7 33 0.5× 56 1.1× 31 0.7× 18 0.6× 11 0.8× 18 117
Méryem-Maud Farhat France 5 15 0.2× 41 0.8× 47 1.0× 33 1.1× 6 0.4× 15 107

Countries citing papers authored by Max Flogegård

Since Specialization
Citations

This map shows the geographic impact of Max Flogegård's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Flogegård with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Flogegård more than expected).

Fields of papers citing papers by Max Flogegård

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Flogegård. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Flogegård. The network helps show where Max Flogegård may publish in the future.

Co-authorship network of co-authors of Max Flogegård

This figure shows the co-authorship network connecting the top 25 collaborators of Max Flogegård. A scholar is included among the top collaborators of Max Flogegård based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Flogegård. Max Flogegård is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Nilsson, Lars, Magnus Tobiasson, Martin Jädersten, et al.. (2025). Influence of Cytogenetics on the Outcome of Patients With High‐Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. Genes Chromosomes and Cancer. 64(2). e70029–e70029. 1 indexed citations
2.
Ekberg, Sara, Karin E. Smedby, Tobias Sjöblom, et al.. (2024). Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers. British Journal of Haematology. 205(5). 1794–1803.
3.
4.
Valachis, Antonios, et al.. (2019). Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome. Acta Oncologica. 58(8). 1170–1177. 13 indexed citations
5.
6.
Valachis, Antonios, et al.. (2018). Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?. Annals of Hematology. 97(11). 2129–2135. 13 indexed citations
7.
Hellman, Urban, Per Westermark, Hareth Nahi, et al.. (2015). A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family. European Journal of Medical Genetics. 58(4). 211–215. 9 indexed citations
8.
Hjorth, Martin, Øyvind Hjertner, Lene Meldgaard Knudsen, et al.. (2012). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European Journal Of Haematology. 88(6). 485–496. 41 indexed citations
9.
Nahi, Hareth, Johan Liwing, Johan O. L. Andreasson, et al.. (2012). Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.. Blood. 120(21). 2970–2970. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Camila Peña Breakdown of academic impact, for papers by Weerasak Nawarawong Breakdown of academic impact, for papers by Donata Sartori Breakdown of academic impact, for papers by Kayleen Bailey Breakdown of academic impact, for papers by Gian Matteo Pica Breakdown of academic impact, for papers by Hong L. Tiv Breakdown of academic impact, for papers by Holly Lee Breakdown of academic impact, for papers by Jorge Monge Breakdown of academic impact, for papers by Chiara Pavoni Breakdown of academic impact, for papers by Méryem-Maud Farhat
Rankless by CCL
2026